anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Aida

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 3,551
Current window 1,051-1,080
Pages 119
Rows per page 30
Arc: Aidaclear collectionreset all
18 30 60

Arc

1,051-1,080 of 3,551

filter-aware
07
Taysha | IPO Presentation Deck | 66 slidesTaysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
08
The slide uses a Gantt-style chart to represent the development status of various gene therapy programs.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
09
The chart uses a staircase/waterfall visualization to show individual disease populations contributing to a total addressable market.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
10
The slide uses an upward-trending arrow diagram to represent progress or acceleration.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
11
The slide uses line charts to illustrate revenue or patient growth trajectories over time (Q1-Q15).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
12
The slide uses a grid layout to associate individuals with their past or current corporate affiliations via logos.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
13
The slide highlights institutional credibility and R&D capabilities through a specific academic partnership.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
14
The slide uses a hub-and-spoke style diagram to show how two entities contribute to a central set of activities.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
15
The background features a faint image of a gel electrophoresis or DNA sequencing result, suggesting a biotech/genomics focus.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Interest1 hit
16
Includes a biological pathway diagram and a clinical progression timeline.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
17
The chart uses a sigmoid-like curve to show the relationship between enzyme activity and disease progression.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
18
The vector uses a P2A self-cleaving linker to ensure 1:1 expression of the two genes under a single promoter.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
19
The chart uses standard statistical significance markers (*, **, ****) to denote p-values against the control group.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
20
The chart displays longitudinal data for five groups: Heterozygote/Vehicle, three dose levels of TSHA-101 in Knockout mice, and Knockout/Vehicle control.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
21
The chart displays statistical significance markers (asterisks) comparing treatment groups to the vehicle control.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
22
The slide uses a table-like structure to define the parameters of a Phase 1/2 clinical trial.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Logic Chain1 hit
23
Includes a diagram of the AAV9-hCLN1 gene therapy construct.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
24
The chart is a standard Kaplan-Meier survival plot used in preclinical efficacy studies.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
25
The chart compares untreated WT, Het, and KO mice against treated mice at 4, 20, and 26 weeks of age.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
26
The slide uses a consistent icon for each pipeline entry.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
27
The background features a DNA gel electrophoresis image, suggesting a biotech or genetic focus.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · Desire1 hit
28
Includes a citation for disease reversibility research.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
29
Includes a visual spectrum diagram showing the relationship between MECP2 expression levels and clinical outcomes.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
30
The slide uses a diagram to illustrate the genetic construct (scAAV ITR, MeP426, miniMECP2, miRARE).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · DesireLoop · Aha Moment1 hit
31
The slide uses a numbered process flow (1-5) to explain a molecular biology mechanism.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
32
The slide shows immunohistochemistry images (NeuN, myc, DAPI, merge) for two experimental conditions across two mouse IDs each.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
33
The slide displays immunofluorescence staining (NeuN, myc, DAPI, merge) across three brain regions (Thalamus, Hippocampus, Brain Stem) for two treatment groups (PHP.B/mini vs PHP.B/mini-miRARE).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
34
The chart shows survival rates over 35 weeks for various dosage groups of AAV9/MECP2 and TSHA-102.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
35
The slide compares TSHA-102 against control and other AAV9 constructs. The bottom box highlights specific adverse event rates (lesions/prolapses).Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit
36
The chart shows survival percentages over time (weeks) for different treatment groups, with diamonds indicating vet-requested euthanasia.Taysha | IPO Presentation Deck | 66 slides · Taysha Gene Therapies
Pitch deck Investment bank Beat · ActionLoop · Aha Moment1 hit